Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-007 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05020015Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of sitocabnagene loxiveluecel in B-cell non-Hodgkin lymphoma (4 arms), sponsored by Takeda. Primary endpoints: Treatment Emergent Adverse Events up to 24 months, Clinically Significant Changes in Laboratory Parameters up to 24 months and 1 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
sitocabnagene loxiveluecel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05020015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020015.